SCHEMBL282839

SCHEMBL282839

COc1cc([N+](=O)[O-])ccc1Br

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.66
TDP1 Q9NUW8 1/20 0.59
LMNA P02545 3/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
PKM P14618 1/20 0.54
AMY1A P0DUB6 2/20 0.52
KMT2A Q03164 5/20 0.49
MEN1 O00255 4/20 0.49
HTR2A P28223 1/20 0.49
ALDH1A1 P00352 2/20 0.49
MAPT P10636 2/20 0.49
CYP19A1 P11511 1/20 0.49
PTGS2 P35354 1/20 0.49
PTPRC P08575 1/20 0.48
S100A4 P26447 1/20 0.48
CRHBP P24387 1/20 0.48
CRHR2 Q13324 1/20 0.48
POLB P06746 1/20 0.48
HPGD P15428 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31144295 0.85 TDP1 (0.64) HTTTDP1LMNASMN1; SMN2PKM
SCHEMBL145997 0.85 TDP1 (0.64) HTTTDP1LMNASMN1; SMN2PKM
SCHEMBL31555017 0.85 HTT (0.50) HTTTDP1LMNASMN1; SMN2PKM
SCHEMBL527567 0.82 HTT (0.72) HTTTDP1LMNASMN1; SMN2PKM
SCHEMBL29441283 0.82 HTT (0.72) HTTTDP1LMNASMN1; SMN2PKM
SCHEMBL4074552 0.81 KMT2A (0.51) HTTTDP1LMNAPKMKMT2A
SCHEMBL30962745 0.81 KMT2A (0.51) HTTTDP1LMNAPKMKMT2A
SCHEMBL2373369 0.81 CYP19A1 (0.57) HTTTDP1LMNASMN1; SMN2PKM
SCHEMBL1579631 0.80 HTT (0.47) HTTTDP1LMNASMN1; SMN2KMT2A
SCHEMBL30727257 0.80 HTT (0.47) HTTTDP1LMNASMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 488 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117843499-A Diamine with asymmetric structure, high-performance polyimide, and preparation methods and applications thereof 华南理工大学 2024-04-09 CN claimed
CN-107973727-A Between disubstituted benzenes phenolic compounds and preparation method thereof and anti-tubercle bacillus application 中山大学 2018-05-01 CN claimed
EP-4642767-A1 PYRIMIDINE CARBOXAMIDE COMPOUNDS Acrivon Therapeutics, Inc. (US) 2025-11-05 EP disclosed
US-20250171431-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE HORIZON THERAPEUTICS IRELAND DAC (IE) 2025-05-29 US disclosed
WO-2025030163-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE HORIZON THERAPEUTICS IRELAND DAC (IE) 2025-02-06 WO disclosed
US-12195452-B2 N-(4-(oxazol-5-yl)phenyl) chromane-3-carboxamide derivatives and related compounds as stimulators of the production of retinal precursor cells for the treatment of neuroretinal diseases ENDOGENA THERAPEUTICS, INC. (US) 2025-01-14 US disclosed
CN-119264119-A Preparation method and application of FLT3 degradation agent based on pyrazinecarboxamide skeleton 中国科学院上海有机化学研究所 2025-01-07 CN disclosed
CN-113227086-B N- (4- (oxazol-5-yl) phenyl) chroman-3-carboxamide derivatives and related compounds as stimulators of production of retinal precursor cells for the treatment of neuroretinal disorders 内生疗法公司 2024-07-26 CN disclosed
US-20240228459-A1 WEE1 INHIBITORS AND USES THEREOF BOUNDLESS BIO, INC. 2024-07-11 US disclosed
WO-2024145505-A1 PYRIMIDINE CARBOXAMIDE COMPOUNDS ACRIVON THERAPEUTICS, INC. (US) 2024-07-04 WO disclosed
CN-117843499-A Diamine with asymmetric structure, high-performance polyimide, and preparation methods and applications thereof 华南理工大学 2024-04-09 CN disclosed
WO-1996002537-A1 BENZOCONDENSED FIVE MEMBERED HETEROCYCLE CARBOXAMIDES AS 5HT2B/2C RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1996-02-01 WO disclosed
US-5474999-A Useful in treatment of urinary incontinence IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1995-12-12 US disclosed
US-5382598-A Therapeutic amides IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1995-01-17 US disclosed
US-5272163-A Therapeutic amides IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-12-21 US disclosed
EP-0524781-A1 Therapeutic amides ZENECA LIMITED (GB) 1993-01-27 EP disclosed
US-4895867-A 2-(5-phenyl-2-furanyl)imidazoles useful as cardiotonic agents NORWICH EATON PHARMACEUTICALS, INC. (US) 1990-01-23 US disclosed
US-4882354-A N-hydroxy-5-phenyl-2-furancarboximidamides useful as cardiotonic agents NORWICH EATON PHARMACEUTICALS, INC. (US) 1989-11-21 US disclosed
EP-0321431-A1 N-hydroxy-5-phenyl-2-furancarboximidamides useful as cardiotonic agents Norwich Eaton Pharmaceuticals, Inc. (US) 1989-06-21 EP disclosed
EP-0251380-A2 2- (5-phenyl-2-furanyl) imidazoles useful as cardiotonic agents Norwich Eaton Pharmaceuticals, Inc. (US) 1988-01-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12195452-B2 N-(4-(oxazol-5-yl)phenyl) chromane-3-carboxamide derivatives and related compounds as stimulators of the production of retinal precursor cells for the treatment of neuroretinal diseases NR2E3, GFRA2, ALDH1A2 HTT 3177/4885TDP1 3901/4885LMNA 3302/4885
US-20250171431-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE IGF1R, TRHR, TSHR HTT 163/4885TDP1 806/4885LMNA 3056/4885
US-20240228459-A1 WEE1 INHIBITORS AND USES THEREOF WEE1, WEE2, DCLRE1B HTT 4248/4885TDP1 332/4885LMNA 3233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.